| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Michael Rose
Jenna Brashear
Jenna Brashear
| Share Statistics | INDV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,878.1 | $579.1 | 67% |
|
| Shares Out (Mil) | 129.0 | 43.0 | 68% |
|
| Institutional Ownership | 98.4% | 84.3% | 79% |
|
| Float (Mil) | 113.0 | 46.8 | 64% |
|
| Beta | 1.15 | 0.62 | 68% |
|
| Avg Daily Volume (000s) | 1,578 | 285 | 78% |
|
| Price Change (52-week) |
129.9% | 63.8% | 94% |
|
| Growth | INDV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 13.9% | 6.7% | 70% |
|
| Net Income (5yr) | 27.9% | (1.4%) | 83% |
|
| EPS (5yr) | 29.4% | 14.9% | 80 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 6.4% | (14.9%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | $0.922 | $3.855 | $4.168 | |
| Month Ago EPS | $0.907 | $3.825 | $4.142 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.920 | $3.927 | $3.820 | |
| Year/Year Chg | 33.6% | 135.1% | 168.7% | |
| Financials | INDV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,290 | $272 | 54% |
|
| Net Income (TTM) (Mil) | $252 | ($11) | 71% |
|
| EPS (TTM) | $2.016 | ($0.500) | 72% |
|
| Operating Cash Flow (TTM) (Mil) | ($111) | ($6) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($198) | $4 | 10% |
|
| Long-Term Debt (Q1) (Mil) | $500 | $7 | 59% |
|
| Enterprise Value (Q1) (Mil) | $5,187 | $522 | 63% |
|
| Valuation | INDV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | 20.5 | 20.5 | 52% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.7 | 1.2 | 34% |
|
| Ratios | INDV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 85.0% | 65.9% | 91% |
|
| Net Margin | 19.5% | 0.7% | 78% |
|
| ROA | 19.6% | (24.6%) | 96% |
|
| ROE | (117.5%) | (19.7%) | 8% |
|
| Liabilities to Assets | 112.0% | 35.5% | 96% |
|
| F-Score | 6 | 3 | na |
|
Indivior Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
